Condition: Minimal Change Disease (MCD) · Sponsor: Medical University Innsbruck
OBELIX-NEPHROSIS (NS) The goal of this clinical trial is to learn if obinutuzumab works to treat minimal change disease in adults. It will also learn about the safety of drug obinutuzumab. The main questions it aims to answer are: Is obinutuzumab non-inferior to glucocorticoids at inducing remission? Does obinutuzumab provide superiority in terms of relapse-free survival after 52 weeks? What medical problems do participants have when receiving obinutuzumab? Researchers will compare drug obinutuzumab to glucocorticoids and aim to phenotype participants with minimal change disease. Participants will: Take the drug obinutuzumab (2 doses) or glucocorticoids Visit the clinic for 8 visits over a period of 52 weeks, plus additional controls when disease relapses occur
This description comes directly from the study's public registry record.
Andreas Kronbichler, M.D. Ph.D. · 004351250425855 · andreas.kronbichler@i-med.ac.at
Philipp Gauckler, M.D. · philipp.gauckler@i-med.ac.at
Always discuss trial participation with your own doctor first.
| Division of Nephrology, Department of Internal Medicine, Medical University of Graz | Graz, Austria | Not Yet Recruiting |
| Department of Internal Medicine IV, Nephrology and Hypertension | Innsbruck, Austria | Recruiting |
| 6. Medizinische Abteilung mit Nephrologie & Dialyse, Klinik Ottakring | Vienna, Austria | Not Yet Recruiting |
| Laboratory of Immunology, Nice University Hospital (CHU de Nice), Côte d'Azur University | Nice, France | Not Yet Recruiting |
| Hôpital Henri-Mondor | Paris, France | Not Yet Recruiting |
| III. Department of Medicine, University Medical Center Hamburg-Eppendorf | Hamburg, Germany | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07710157